Home » Stocks » ACRX

AcelRx Pharmaceuticals, Inc. (ACRX)

Stock Price: $1.18 USD -0.03 (-2.48%)
Updated Aug 3, 2021 12:28 PM EDT - Market open
Market Cap 144.11M
Revenue (ttm) 5.54M
Net Income (ttm) -33.41M
Shares Out 113.26M
EPS (ttm) -0.36
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day August 3
Last Price $1.18
Previous Close $1.21
Change ($) -0.03
Change (%) -2.48%
Day's Open 1.20
Day's Range 1.16 - 1.21
Day's Volume 425,832
52-Week Range 1.02 - 2.94

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) between March 17, 2020 and February...

14 hours ago - Business Wire

AcelRx Pharmaceuticals (ACRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

20 hours ago - Zacks Investment Research

NEW YORK--(BUSINESS WIRE)--Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ("AcelRx" or "the ...

1 day ago - Business Wire

NEW YORK, July 28, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX) and certain of ...

5 days ago - PRNewsWire

BENSALEM, Pa., July 28, 2021 /PRNewswire/ -- Law Offices of Howard G.

6 days ago - PRNewsWire

NEW YORK, July 26, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) between March 17, 2020...

1 week ago - PRNewsWire

LOS ANGELES, July 23, 2021 /PRNewswire/ --   Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming  August 9, 2021 deadline to file a lead plaintiff motion in the class action filed on b...

1 week ago - PRNewsWire

LOS ANGELES, July 21, 2021 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Ac...

1 week ago - PRNewsWire

New York, New York--(Newsfile Corp. - July 20, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) between...

1 week ago - Newsfile Corp

NEW YORK, July 18, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX) and certain of ...

2 weeks ago - PRNewsWire

New York, New York--(Newsfile Corp. - July 17, 2021) - WHY: New York, N.Y., July 17, 2021. Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AcelRx Pharmaceutica...

2 weeks ago - Newsfile Corp

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) between March 17, 2020 and February...

2 weeks ago - Business Wire

AcelRx (ACRX) enters a licensing agreement for Dzuveo in Europe and an in-licensing agreement for two products in the United States.

2 weeks ago - Zacks Investment Research

Are these Reddit penny stocks worth adding to your small-caps watchlist right now? The post 5 Reddit Penny Stocks to Watch That Are Moving Right Now appeared first on Penny Stocks to Buy, Picks, News an...

Other stocks mentioned: BBD, CEI, EARS, VERB
2 weeks ago - PennyStocks

New York, New York--(Newsfile Corp. - July 14, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) between...

2 weeks ago - Newsfile Corp

AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) has agreed to provide a license to Laboratoire Aguettant to commercialize Dzuveo in Europe and give AcelRx two prefilled syringe product candidates for the U.S....

2 weeks ago - Benzinga

HAYWARD, Calif., July 14, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative th...

2 weeks ago - PRNewsWire

New York, New York--(Newsfile Corp. - July 13, 2021) -  Pomerantz LLP announces that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX)...

2 weeks ago - Newsfile Corp

San Diego, California and Hayward, California--(Newsfile Corp. - July 8, 2021) - Shareholder rights law firm Robbins LLP reminds investors that a class action has been filed on behalf of all purchasers ...

3 weeks ago - Newsfile Corp

NEW YORK, July 4, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) between March 17, 2020 ...

4 weeks ago - PRNewsWire

SAN DIEGO & HAYWARD, Calif.--(BUSINESS WIRE)---- $ACRX #ACELRX--Shareholder rights law firm Robbins LLP reminds investors that a class action has been filed on behalf of all purchasers of AcelRx Therape...

1 month ago - Business Wire

BENSALEM, Pa., July 1, 2021 /PRNewswire/ -- Law Offices of Howard G.

1 month ago - PRNewsWire

New York, New York--(Newsfile Corp. - June 25, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) between...

1 month ago - Newsfile Corp

LOS ANGELES, June 25, 2021 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Ac...

1 month ago - PRNewsWire

New York, New York--(Newsfile Corp. - June 24, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ("AcelRx" or ...

1 month ago - Newsfile Corp

NEW YORK--(BUSINESS WIRE)-- #ACRX--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) between March 17, 2020 and ...

1 month ago - Business Wire

LOS ANGELES, June 23, 2021 /PRNewswire/ --  Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming  August 9, 2021 deadline to file a lead plaintiff motion in the class action filed on be...

1 month ago - PRNewsWire

NEW YORK, June 22, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX) and certain of ...

1 month ago - PRNewsWire

NEW YORK, June 17, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) between March 17, 2020...

1 month ago - PRNewsWire

NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ("AcelRx" or "the C...

1 month ago - Business Wire

HAYWARD, Calif., June 17, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative th...

1 month ago - PRNewsWire

NEW YORK, June 16, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX) and certain of ...

1 month ago - PRNewsWire

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming August 9, 2021 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purc...

1 month ago - Business Wire

Q.ai runs daily factor models to get the most up-to-date reading on stocks and ETFs. Today, our deep-learning algorithms have identified American Express Company among others.

Other stocks mentioned: AXP, ARE, MO, SPRO
1 month ago - Forbes

LOS ANGELES--(BUSINESS WIRE)---- $ACRX #investors--The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of AcelRx Pharmaceuticals, Inc. (ACRX) Investors

1 month ago - Business Wire

SAN DIEGO & HAYWARD, Calif.--(BUSINESS WIRE)---- $ACRX #ACRX--Shareholder rights law firm Robbins LLP announces that a class action has been filed on behalf of all purchasers of AcelRx Therapeutics, Inc...

1 month ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- $ACRX #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf o...

1 month ago - Business Wire

NEW YORK, June 11, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of AcelRx Pharmac...

1 month ago - PRNewsWire

LOS ANGELES--(BUSINESS WIRE)---- $ACRX #ACRX--SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc.

1 month ago - Business Wire

BENSALEM, Pa.--(BUSINESS WIRE)---- $ACRX #CLASSACTION--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased AcelRx Pharmaceuticals, In...

1 month ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- $ACRX #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf...

1 month ago - Business Wire

NEW YORK, June 10, 2021 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ("Ac...

1 month ago - PRNewsWire

LOS ANGELES--(BUSINESS WIRE)---- $ACRX #investors--The Law Offices of Frank R. Cruz Announces Investigation of AcelRx Pharmaceuticals, Inc. (ACRX) on Behalf of Investors

1 month ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- $ACRX #ACRX--SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc.

1 month ago - Business Wire

BENSALEM, Pa.--(BUSINESS WIRE)---- $ACRX #CLASSACTION--Law Offices of Howard G. Smith announces an investigation on behalf of AcelRx Pharmaceuticals, Inc. (“AcelRx” or the “Company”) (NASDAQ: ACRX) inve...

1 month ago - Business Wire

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of AcelRx Pharmaceuticals, Inc...

1 month ago - Business Wire

NEW YORK--(BUSINESS WIRE)-- #AcelRX--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States District ...

1 month ago - Business Wire

NEW YORK, June 8, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX) and certain of i...

1 month ago - PRNewsWire

HAYWARD, Calif., June 1, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative the...

2 months ago - PRNewsWire

HAYWARD, Calif., May 26, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative the...

2 months ago - PRNewsWire

About ACRX

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. The company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. It also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
Feb 14, 2011
CEO
Vincent Angotti
Employees
54
Stock Exchange
NASDAQ
Ticker Symbol
ACRX
Full Company Profile

Financial Performance

In 2020, ACRX's revenue was $5.42 million, an increase of 136.61% compared to the previous year's $2.29 million. Losses were -$40.38 million, -24.16% less than in 2019.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for ACRX stock is "Buy." The 12-month stock price forecast is 6.67, which is an increase of 465.25% from the latest price.

Price Target
$6.67
(465.25% upside)
Analyst Consensus: Buy